Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).

• Status: Recruiting
• Trial end date: 2025-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Beta-blockers have the greatest cardiovascular impact in patients with reduced heart function/heart failure and in reducing the peri-operative risk of atrial fibrillation. In patients without these high-risk features treated with coronary artery bypass graft (CABG) surgery, their continued long-term role is unclear.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Saskatchewan
• Collaborator: Canadian VIGOUR Centre
• Treatments: Adrenergic beta-Antagonists

Criteria

Inclusion Criteria:

• Age ≥ 18 years treated with index isolated CABG

• Able to consent to study

• On beta blocker therapy at the 6-8week visit

• LV systolic function (≥45% assessed within 6months of CABG date)

Exclusion Criteria:

• Prior heart failure with reduced ejection fraction (LVEF <45%)

• Pre- or peri-operative atrial fibrillation or flutter

• Peri-CABG stroke

• Unable to follow-up